IBAB Ion Beam Applications SA

IBA - Transparency notification

IBA - Transparency notification

Louvain-la-Neuve, Belgium, May 24, 2019, 17.35



Summary of the notification

IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on May 24, 2019.

In its notification, Norges Bank has notified, that following an acquisition of IBA shares with voting rights and a disposal of equivalent financial instruments, its total holding in IBA SA has increased but its holding in equivalent financial instruments has crossed downwards the 3 % threshold on May 23, 2019.

In details, on May 2019, 2019, Norges Bank owned (A) 198.433 IBA shares with voting rights (versus 106.079 shares in its previous notification), representing 0,66% of the total number of shares issued by IBA (30 122 528) (versus 0,35% in its previous notification), as well as (B) 887.920 equivalent financial instruments (versus 920.935 in its previous notification) representing 2,95%of the total number of shares issued by IBA (30 122 528) (versus 3,06% in its previous notification).

Content of the notification

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights
  • Persons subject to the notification requirement: Norges Bank
  • Date on which the threshold is crossed: 23/05/2019
  • Threshold crossed (in %): 3%
  • Denominator: 30 122 528
  • Notified details: (extract of the received notification form)

               
A) Voting rightsPrevious notificationAfter the transaction 
 # of voting rights# of voting rights% of voting rights 
Holders of voting rights  Linked to securities Not linked to the securitiesLinked to securitiesNot linked to the securities 
Norges Bank106.079198.433 0,66%  
 TOTAL198.43300,66%0,00% 
       
B) Equivalent financial instrumentsAfter the transaction
Holder of equivalent financial instruments Type of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
Norges BankShares on loan (right to recall) At any time887.9202,95%physical
 TOTAL 887.9202,95% 
       
 TOTAL (A & B)  # of voting rights%of voting rights 
    1.086.3533,61% 
  • Full chain of controlled undertakings through which the holding is effectively held:

Norges Bank is the central bank of Norway. As part of its central bank activities, Norges Bank manages Norway’s foreign exchange reserves and is responsible for management of the Norwegian Government Pension Fund Global (GPFG). The formal responsibility for management of the GPFG is placed with the Ministry of Finance, but is delegated to Norges Bank. All investments are executed by Norges Bank acting as principal and all holdings are registered in the name of Norges Bank.

For further information, please contact:

IBA

Stephanie Bauwin

Legal Counsel



About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at:



Attachment

EN
24/05/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

Guy Sips ... (+9)
  • Guy Sips
  • Hilde Van Boxstael
  • Kristof Samoy
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Morning Notes : ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HY...

: ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HYL BB, IBAB BB, KIN BB, MTLS US, VGP BB, AZE BB, ZEAL DC

 PRESS RELEASE

IBA and Shreeji sign multi‑site agreement for four cyclotrons to expan...

IBA and Shreeji sign multi‑site agreement for four cyclotrons to expand PET radiopharmaceutical manufacturing across India Louvain-la-Neuve, Belgium – 19 February 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, and Shreeji (Shreeji Imaging and Diagnostic Centre Pvt. Ltd.), a leading Indian manufacturer and distributor of fluorodeoxyglucose (FDG) and positron emission tomography (PET) radiopharmaceuticals, have signed a multi-site agreement for the delivery and installation of four mid-en...

 PRESS RELEASE

IBA et Shreeji signent un accord pour quatre cyclotrons afin d’étendre...

IBA et Shreeji signent un accord pour quatre cyclotrons afin d’étendre la production de radiopharmaceutiques TEP en Inde Louvain-la-Neuve, Belgium – 19 février 2026 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d'accélérateurs de particules et acteur de premier plan en médecine nucléaire, et Shreeji (Shreeji Imaging and Diagnostic Centre Pvt. Ltd.), l'un des principaux fabricants et distributeurs indiens de fluorodéoxyglucose (FDG) et de radiopharmaceutiques pour la tomographie par émission de positons (TEP), ont signé un contrat pour la livraison et l'i...

 PRESS RELEASE

IBA – ACQUISITION OF OWN SHARES

IBA – ACQUISITION OF OWN SHARES Louvain-la-Neuve, Belgium, February 16th, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026. Under this program, IBA has requested a financial intermediary to repurchase up to 400,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until September 30th, 2026 (included), effective as from February 3rd, 2...

 PRESS RELEASE

IBA – ACQUISITION D’ACTIONS PROPRES

IBA – ACQUISITION D’ACTIONS PROPRES Louvain-la-Neuve, Belgique, 16 février 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 2 février 2026. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 400.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 30 septembre 2026 et effectif ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch